Bicara Therapeutics (BCAX)
Developing a bifunctional antibody program for head and neck and other solid tumors.
Something off on this page? Send us feedback.
Develops clinical-stage cancer therapies centered on ficerafusp alfa, an EGFR/TGF-beta antibody program in head and neck cancer. The business is pre-commercial and depends on advancing one lead asset through clinical development, with broader expansion aimed at other solid tumors.
Develops oncology therapies around ficerafusp alfa, a bifunctional EGFR/TGF-beta antibody for head and neck squamous cell carcinoma. Current work is centered on the FORTIFI-HN01 study and on extending the program into other EGFR-expressing solid tumors.
Operates as a clinical-stage company rather than a diversified drug seller. Research and development drive the model, with operations centered in Boston and clinical activity organized around one lead asset, one core disease setting, and a small current workforce.
Execution depends on trial enrollment, readouts, and regulatory interaction, including the FDA Breakthrough Therapy path for the lead regimen in a defined head and neck setting. Commercial preparation is beginning, but the business remains shaped by progress in one program and by combination use with pembrolizumab.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 22, 2026 | HSBC | Downgrade | Rating: — | |
| Aug 18, 2026 | BMO Capital | Initiate | Rating: —Target: — | Target: $35 |
| Aug 12, 2026 | Wedbush | Reiterate | Rating: —Target: — | Target: $33 |
| Aug 12, 2026 | BTIG | Reiterate | Rating: —Target: $28 | Target: $39 |
| Aug 12, 2026 | Mizuho Securities | Target | Target: $18 | Target: $20 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $497.3M · Total debt $1.2M · Total assets $512.2M · Shareholders' equity $468.8M
- Revenue
- $0
- Operating income
- −$60.0M
- Net income
- −$55.4M
No dividends on record.
| Institutions | ≈ 109.25% | 72.30M shares | |
|---|---|---|---|
| 183 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.10% | 728.9K shares | |
| 4 holders · as of Sep 10, 2026 | |||
| Strategic holders | 5.05% | 3.34M shares | |
| 1 holder · as of May 15, 2026 | |||
| Adds to | 115.40% | ||
66.17M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 115.40%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 10.97% | 7.26M | as of Jun 30, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 9.58% | 6.34M | as of Jun 30, 2026 |
Siren, L.L.C.Institution | 8.47% | 5.60M | as of Jun 30, 2026 |
Vestal Point Capital, LPInstitution | 7.93% | 5.25M | as of Jun 30, 2026 |
Deep Track Capital, LPInstitution | 6.20% | 4.10M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 8, 2026 | Ryan Cohlhepp | director, officer: President, COO & Interim CEO | −17,500 | $22.90 |
| Aug 10, 2026 | Ryan Cohlhepp | director, officer: President and COO | −18,750 | $27.98 |
| Aug 10, 2026 | Claire Mazumdar | director, officer: Chief Executive Officer | −10,000 | $27.98 |
| Aug 10, 2026 | Ivan Hyep | officer: Chief Financial Officer | −12,500 | $27.97 |
| Jul 10, 2026 | Claire Mazumdar | director, officer: Chief Executive Officer | −10,000 | $28.42 |
- Merck
KEYTRUDA sets the PD-1 backbone in 1L R/M HNSCC
- Johnson & Johnson
EGFRxMET amivantamab is moving into 1L HNSCC combinations
- Regeneron
Dual-checkpoint fianlimab+cemi targets the same 1L HNSCC slot
- Eli Lilly
ERBITUX remains the incumbent EGFR antibody in HNSCC
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Bicara Therapeutics | $21.54 | −5.42% | $1.50B | — | — | — | — |
| Merck | $147.86 | −2.02% | $372.73B | 120.7 | 17.1 | 5.6 | +5.1% |
| Johnson & Johnson | $269.90 | +0.26% | $648.72B | 31.2 | 22.7 | 6.6 | +6.6% |
| Regeneron | $795.63 | −1.03% | $82.82B | 19.9 | 13.1 | 5.3 | +16.7% |
| Eli Lilly | $1,159.49 | −0.91% | $1.10T | 39.3 | 28.3 | 13.8 | +47.7% |
| Median | 35.2 | 19.9 | 6.1 | +11.7% |